• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

    18.59 -0.64 (-3.33%)
    Streaming Delayed Price Updated: 3:06 PM EDT, Oct 29, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,732,973
    Open 19.34
    Bid (Size) 18.58 (2)
    Ask (Size) 18.61 (1)
    Prev. Close 19.23
    Today's Range 18.43 - 19.34
    52wk Range 15.55 - 36.91
    Shares Outstanding 97,381,774
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Wall Street Is Backing These 3 Comeback Stocks
    Via MarketBeat
    1 Monster Stock in the Making to Buy and Hold
    The company's prospects improve with every clinical win. 
    Via The Motley Fool

    Performance

    YTD
    +1.3%
    +1.3%
    1 Month
    -12.1%
    -12.1%
    3 Month
    -30.5%
    -30.5%
    6 Month
    -21.3%
    -21.3%
    1 Year
    -16.4%
    -16.4%

    More News

    Read More
    Summit Therapeutics: A Risky Bet in the Biotech Arena?
    Via The Motley Fool
    Summit Therapeutics Raises $500 Million in Private Placement
    From Summit Therapeutics
    Via Business Wire
    Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40%
    Via Stocktwits
    An Overview of Summit Therapeutics's Earnings
    Via Benzinga
    Summit Therapeutics Stock Draws Cautious Retail Mood After Barclays ‘Underweight’ Call: ‘Added To The Biotech Graveyard’
    Via Stocktwits
    What's Going On With Summit Therapeutics Stock On Monday?
    Via Benzinga
    Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More
    Via Benzinga
    Summit Therapeutics Inc (NASDAQ:SMMT) Reports Wider-Than-Expected Q3 2025 Loss
    Via Chartmill
    Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
    From Summit Therapeutics
    Via Business Wire
    Earnings Scheduled For October 20, 2025
    Via Benzinga
    Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
    From Summit Therapeutics
    Via Business Wire
    Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
    From Summit Therapeutics
    Via Business Wire
    Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
    From Summit Therapeutics
    Via Business Wire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    1 Monster Stock in the Making to Buy and Hold
    Via The Motley Fool
    Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence
    Via Benzinga
    Intel, Marvell, Electronic Arts Are Among The Top 10 Large-Cap Gainers Last Week (Sep. 22 - Sep. 26): Are The Others In Your Portfolio?
    Via Benzinga
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
    From Pomerantz LLP
    Via GlobeNewswire
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics
    Via Business Wire
    HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
    From Summit Therapeutics
    Via Business Wire
    Nvidia High-Fives Palantir, Rocket Lab — On This List Of '10-Bagger' Legends
    Via Benzinga
    This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
    Via Benzinga
    Jim Cramer: Ring The Register On This Real Estate 'Meme' Stock
    Via Benzinga

    Frequently Asked Questions

    Is Summit Therapeutics Inc. - Common Stock publicly traded?
    Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Summit Therapeutics Inc. - Common Stock trade on?
    Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
    The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
    What is the current price of Summit Therapeutics Inc. - Common Stock?
    The current price of Summit Therapeutics Inc. - Common Stock is 18.59
    When was Summit Therapeutics Inc. - Common Stock last traded?
    The last trade of Summit Therapeutics Inc. - Common Stock was at 10/29/25 03:06 PM ET
    What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
    The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.81B
    How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
    Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.